Background Long‐term therapy for psoriasis is impaired by gradual loss of effectiveness and
treatment discontinuation. Identifying factors that affect biologic drug survival may help in …

Drug survival studies have been utilized to evaluate the real-world effectiveness of biologics
used in psoriasis. However, the increasing volume of drug survival data suffers from large …

Importance Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to
psoriatic inflammation. Objective To evaluate the efficacy and safety of risankizumab vs …

Drug survival of biologics represents their real-world effectiveness and safety. We conducted
a meta-analysis of real-world evidence on the drug survival of biologics in treating psoriasis …

Generalized pustular psoriasis (GPP) is a rare, potentially life‐threatening inflammatory skin
disease. Our aim was to assess patient and disease characteristics and analyze drug …

To compare drug survival of ixekizumab to other IL‐17 inhibitors (IL‐17i) and TNF inhibitors
(TNFi) among patients with psoriasis (PsO) in a real‐world setting. Participants included …

Introduction Biologic treatments for psoriasis are commonly switched. Treatment persistence
represents an important parameter related to long-term therapeutic performance. The …

Background Given the chronic nature of psoriasis and the loss of response that can be
observed with therapies over time, it is important to understand the long-term efficacy of new …

Background Real-world data on treatment patterns associated with use of interleukin-17A
inhibitors in psoriasis are lacking. Objective To compare treatment patterns between …

Psoriasis is a chronic immune-mediated inflammatory disease affecting women of
childbearing potential. Biologic agents, notably Tumor Necrosis Factor inhibitors (TNFi), are …